News | June 03, 2021
Haffkine Biopharma to produce 22.8 Cr doses of Covaxin
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips
Financial support is being provided as a grant from the Government of India
The company is working closely with its six manufacturing partners in India
Subscribe To Our Newsletter & Stay Updated
